Remission outcomes in severe eosinophilic asthma with mepolizumab therapy: Analysis of the REDES study

Remission outcomes in severe eosinophilic asthma with mepolizumab therapy: Analysis of the REDES study

IntroductionClinical remission as a multicomponent treatment goal in severe asthma is being explored in clinical practice. This post hoc analysis used data from the REDES study to assess the proportion of patients with severe eosinophilic asthma achieving our multicomponent definitions of clinical r...

Volledige beschrijving

Bibliografische gegevens
Hoofdauteurs:	Ian Pavord, Frances Gardiner, Liam G. Heaney, Christian Domingo, Robert G. Price, Alison Pullan, John Oppenheimer, Guy Brusselle, Hiroyuki Nagase, Geoffrey Chupp, Emilio Pizzichini, David Bañas-Conejero, Peter Howarth
Formaat:	Artikel
Taal:	English
Gepubliceerd in:	Frontiers Media S.A. 2023-04-01
Reeks:	Frontiers in Immunology
Onderwerpen:	severe asthma remission clinical outcomes real-world eosinophil biology mepolizumab
Online toegang:	https://www.frontiersin.org/articles/10.3389/fimmu.2023.1150162/full

Gelijkaardige items

A Case of Eosinophilic Gastroenteritis Remission Achieved Steroid-Free With Mepolizumab
door: Yuki Hirata, et al.
Gepubliceerd in: (2022-01-01)

Safety and effectiveness of mepolizumab therapy in remission induction therapy for eosinophilic granulomatosis with polyangiitis: a retrospective study
door: Masanobu Ueno, et al.
Gepubliceerd in: (2022-06-01)

Mepolizumab in the treatment of eosinophilic chronic obstructive pulmonary disease
door: Mkorombindo T, et al.
Gepubliceerd in: (2019-08-01)

Evaluation of Clinical Remission in Best-Performing Severe Asthmatic Patients Treated for Three Years with Mepolizumab
door: Diego Bagnasco, et al.
Gepubliceerd in: (2024-04-01)

Efficacy of add-on mepolizumab in adolescents with severe eosinophilic asthma
door: Steven W. Yancey, et al.
Gepubliceerd in: (2019-09-01)

Patient profiles and clinical utility of mepolizumab in severe eosinophilic asthma
door: Haldar P
Gepubliceerd in: (2017-06-01)

Mepolizumab-responsive recurrent eosinophilic eruption without peripheral eosinophilia
door: Nina B. Curkovic, MD, et al.
Gepubliceerd in: (2024-11-01)

The clinical question of mepolizumab in the long-term treatment of idiopathic chronic eosinophilic pneumonia; how long should we use mepolizumab?
door: Masamitsu Hamakawa, et al.
Gepubliceerd in: (2024-01-01)

Effectiveness and safety of mepolizumab in combination with corticosteroids in patients with eosinophilic granulomatosis with polyangiitis
door: Masanobu Ueno, et al.
Gepubliceerd in: (2021-03-01)

Effectiveness of mepolizumab for eosinophilic pneumonia following bronchial thermoplasty
door: Ryota Otoshi, et al.
Gepubliceerd in: (2020-03-01)

Clinical efficacy of mepolizumab in the treatment of severe eosinophilic asthma in children
door: V. N. Drozdov, et al.
Gepubliceerd in: (2020-11-01)

Real-life efficacy and safety of mepolizumab for eosinophilic granulomatosis with polyangiitis
door: Giuseppe A. Ramirez, et al.
Gepubliceerd in: (2022-12-01)

Severe eosinophilic asthma: from the pathogenic role of interleukin-5 to the therapeutic action of mepolizumab
door: Pelaia C, et al.
Gepubliceerd in: (2017-10-01)

May mepolizumab used in asthma correct subfertility?
door: Guzin Ozden, et al.
Gepubliceerd in: (2021-01-01)

Allergic bronchopulmonary aspergillosis complicated by eosinophilic chronic rhinosinusitis successfully treated with mepolizumab
door: Nobuhiro Matsumoto, et al.
Gepubliceerd in: (2019-10-01)

Experience with mepolizumab in adults with severe eosinophilic asthma: a case series from India
door: Venkata Nagarjuna Maturu, et al.
Gepubliceerd in: (2021-08-01)

Efficacy of mepolizumab for patients with severe asthma and eosinophilic chronic rhinosinusitis
door: Takanori Numata, et al.
Gepubliceerd in: (2019-10-01)

Clinical Remission Criteria and Serum Levels of Type 2 Inflammation Mediators during 24 Weeks of Treatment with the Anti-IL-5 Drug Mepolizumab in Patients with T2-High Severe Asthma
door: Jolita Palacionyte, et al.
Gepubliceerd in: (2024-06-01)

Mepolizumab asthma treatment failure due to refractory airway eosinophilia, which responded to benralizumab
door: Alistair Cook, et al.
Gepubliceerd in: (2021-05-01)

Predictors of the enhanced response to mepolizumab treatment for severe eosinophilic asthma: A retrospective, long-term study
door: Takanori Numata, et al.
Gepubliceerd in: (2020-01-01)

Real-world outcomes of mepolizumab for the treatment of severe eosinophilic asthma in Canada: an observational study
door: Kenneth R. Chapman, et al.
Gepubliceerd in: (2024-02-01)

Response to case report: Airway autoimmune responses in severe eosinophilic asthma following low-dose Mepolizumab therapy
door: I. J. Pouliquen, et al.
Gepubliceerd in: (2017-11-01)

Mepolizumab para el tratamiento de asma grave eosinofílica
door: Armando Partida-Gaytán, et al.
Gepubliceerd in: (2021-01-01)

When sequential use of mepolizumab and dupilumab in a severe atopic eosinophilic asthmatic questions the role of eosinophils in mediating the clinical expression of the disease: a case report
door: M. Sabbe, et al.
Gepubliceerd in: (2024-01-01)

Mepolizumab exerts crucial effects on glucocorticoid discontinuation in patients with eosinophilic granulomatosis with polyangiitis: a retrospective study of 27 cases at a single center in Japan
door: Takashi Yamane, et al.
Gepubliceerd in: (2023-06-01)

Mepolizumab Therapy for Recalcitrant Eosinophilic Annular Erythema in an Adult: A Case Report and Review of Treatment Options
door: Magdalena Żychowska, et al.
Gepubliceerd in: (2020-06-01)

Case Report: Mepolizumab in the treatment of idiopathic chronic eosinophilic pneumonia [version 3; peer review: 2 approved]
door: Moetemri Zied, et al.
Gepubliceerd in: (2023-09-01)

Real-world outcomes of mepolizumab treatment in severe eosinophilic asthma patients - retrospective cohort study in Slovakia
door: Milos Jesenak, et al.
Gepubliceerd in: (2023-09-01)

Idiopathic hypereosinophilic syndrome with eosinophilic cellulitis-like cutaneous involvement treated with mepolizumab and dapsone
door: Madeleine Lachance, MD, et al.
Gepubliceerd in: (2022-04-01)

Combination effect of Mepolizumab and Endobronchial Watanabe Spigot (EWS) in drug‐induced eosinophilic pneumonia complicated by refractory pneumothorax
door: Nana Ayame, et al.
Gepubliceerd in: (2024-09-01)

Switching from omalizumab to mepolizumab therapy improved extra‐pulmonary abdominal and cutaneous vasculitis symptoms in a patient with eosinophilic granulomatosis with polyangiitis
door: Yu‐Hsuan Chen, et al.
Gepubliceerd in: (2022-01-01)

Role of mepolizumab in severe allergic asthma with vocal cord polyp
door: Azmat Karim, et al.
Gepubliceerd in: (2022-01-01)

Very long-term data on patients with severe eosinophilic asthma treated with mepolizumab: a case series
door: Carlo Lombardi, et al.
Gepubliceerd in: (2024-07-01)

Mepolizumab improves clinical outcomes in patients with severe asthma and comorbid conditions
door: Peter G. Gibson, et al.
Gepubliceerd in: (2021-06-01)

Severe asthma remaining well‐controlled after mepolizumab discontinuation: A case report and literature review
door: Takahiro Matsuyama, et al.
Gepubliceerd in: (2023-06-01)

Long-term mepolizumab treatment reduces relapse rates in super-responders with eosinophilic granulomatosis with polyangiitis
door: Nami Masumoto, et al.
Gepubliceerd in: (2023-05-01)

Severe eosinophilic bronchial asthma: new therapeutic options
door: N. M. Nenasheva
Gepubliceerd in: (2018-10-01)

Low-dose anti-IL 5 treatment in idiopathic hypereosinophilic syndrome: towards a precision medicine approach for remission maintenance
door: Marco Caminati, et al.
Gepubliceerd in: (2023-09-01)

Gastrointestinal Involvement of Eosinophilic Granulomatosis with Polyangiitis with Histological Evidence of Treatment Response
door: Mark Lai, et al.
Gepubliceerd in: (2023-03-01)

Economic evaluation and budgetary burden of mepolizumab in severe refractory eosinophilic asthma
door: Manuel David Gil-Sierra, et al.
Gepubliceerd in: (2019-11-01)